CD34 and myelodysplastic syndrome: Pavlaki et al. have shown a decreased gene expression of the cyclin-dependent kinase inhibitors CDKN1A, CDKN2A, and CDKN2B in BM-MSCs in patients with MDS and an impaired capacity to promote the differentiation of CD34+ cells to myeloid and erythroid lineage.